Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2022

Évaluation de la TEV, du MACE et des infections graves chez les patients PR traités par le baricitinib par rapport au TNFi : Une étude multi-bases de données de patients en soins de routine, utilisant des registres de maladies et bases de données des réclamations

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00505-1

Bower H,

Song Y,

Bosan R,

Zhu B,

Mai X,

Deberdt W; B023 Study Consortium

Salinas, et al. evaluate baricitinib safety with respect to VTE, MACE, and serious infection relative to TNFi in patients with RA, in routine care and observe an increased risk of VTE in patients taking baricitinib, compared to TNFi.

Keywords:

February 2019

Innocuité Cardiovasculaire Pendant le Traitement par Baricitinib dans la Polyarthrite Rhumatoïde

Arthritis Rheumatol. 2019 Jul;71(7):1042-1055.

Witt S,

Issa M,

Zhang X,

This study indicates no association between exposure to BARI and MACE, arterial thrombotic events (ATE), or congestive heart failure (CHF). Overall IRs for venous thromboembolic event (VTE) in BARI-treated patients falls within the reported range for patients with RA.RA patients have a greater risk of cardiovascular (CV) diseases of arterial ischemic origin, and an increased risk of VTE. Studied frequencies of thromboembolic events in RA populations in the last decade has been reported as 2–3x h...